Russian Pharmaceutical Industry Leader

Products

Modena®
Pharmacotherapeutic group
Immunosuppressant, multiple sclerosis drug
International name
Fingolimod
Dosage form
Capsules
Description Manufacturer Pharmacies Leave a feedback
Multiple sclerosis drug. Fingolimod is a is a sphingosine-1-phosphate (S1P) receptor modulator. It is metabolized by sphingosine kinase into fingolimod-phosphate, its active metabolite. At low nanomolar concentrations, fingolimod-phosphate binds to lymphocyte S1Р-receptors of type 1, 2, ,3, and 4 and quickly crosses the blood–brain barrier (BBB) binding to neuron S1Р-receptors of type 1, 2, ,3, and 4. By binding S1P-receptors of lymphocytes, fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, resulting in re-distribution of lymphocytes in the body. At the same time, there is no decrease in total lymphocyte counts in the body. Re-distribution of lymphocytes leads to a decrease in lymphocytic infiltration into the central nervous system, severity of inflammation, and nervous tissue damage.
Send
NAME AND SURNAME*
E-mail
Subject*
Message*
Captcha*
* — Required field